Re: Magone et al.: Ocular adverse effects of infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor (Ophthalmology. 2021;128:624–626) Correspondence

  

Authors:	Francis, J. H.; Canestraro, J.; Abramson, D. H.
Title:	Re: Magone et al.: Ocular adverse effects of infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor (Ophthalmology. 2021;128:624–626)
Journal Title:	Ophthalmology
Volume:	128
Issue:	9
ISSN:	0161-6420
Publisher:	Elsevier Science, Inc.
Date Published:	2021-09-01
Start Page:	e43
End Page:	e44
Language:	English
DOI:	10.1016/j.ophtha.2021.05.012
PUBMED:	34167830
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112335470&doi=10.1016%2fj.ophtha.2021.05.012&partnerID=40&md5=1273ad3e6a750ecea61590cc5c5c7d61
Notes:	Letter -- Export Date: 1 September 2021 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/186064